Abiopharma

Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis

CAPR截止日期：Rosen Law Firm敦促遭受損失的Capricor Therapeutics, Inc. (NASDAQ: CAPR)股東與法律事務所聯絡以瞭解有關其權利的資訊

CAPR截止日期：Rosen Law Firm敦促蒙受损失的Capricor Therapeutics, Inc. (NASDAQ: CAPR) 股东与律所联系以了解有关其权利的信息

Best Cheap Electric Cars for Budget-Conscious Drivers in 2025

How to Change Your Passcode on iPhone

Everything We Know About iPhone 17 (2025)

What To Do If Some Of Your iCloud Data Isn’t Syncing

What is the Internet Protocol (IP)? Network Communication Guide

IDEAYA Biosciences and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-in-Class DLL3 TOP1 ADC, in Small Cell Lung Cancer at the IASLC 2025 World Conference on Lung Cancer

Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial

Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting

Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints

TAGRISSO® (osimertinib) plus chemotherapy demonstrated a median overall survival of nearly four years, the longest benefit ever reported in a global Phase III trial in EGFR-mutated advanced lung cancer

Ivonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332

Nuvation Bio Inc. - Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer